The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.

CompletedOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Pancreatic Cancer
Interventions
OTHER

diffusion-weighted MRI

Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.

Trial Locations (1)

641-8510

Wakayama Medical University, Wakayama

All Listed Sponsors
lead

Wakayama Medical University

OTHER

NCT02777463 - The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT. | Biotech Hunter | Biotech Hunter